Moreover, the lack of BCL2L13 is associated with a non-response to preoperative chemoradiotherapy (pCRT) in locally advanced rectal cancer patients, providing a potential strategy to predict pCRT efficacy in rectal cancer patients [5]. This evidence concerns the gene BCL2L13 and rectal cancer.